the effect of treatment of helicobacter pylori (HP) infection on improvement of metabolic syndrome (MS)

study of effects of helicobacter pylori infection on improvement of metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015020420951N1

Enrollment

Registered

2015-03-09

Start date

2015-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: metabolic syndrome. Condition 2: Helicobacter pylori infection. Metabolic disorder, unspecified Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: case group: treatment of HP infection woth opemrazole (20 mg bid), amoxicilin (1gr bid), and clarythromycin (500 mg bid). Intervention 2: the control group will receive only symptomati

Treatment - Drugs

case group: treatment of HP infection woth opemrazole (20 mg bid), amoxicilin (1gr bid), and clarythromycin (500 mg bid)

the control group will receive only symptomatic therapy. the HP treatment postponed until the end of the study (if they provide informed consent)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion: concomitant metabolic syndrome and helicobacter pylori exclusion: no consent; any other internal or cardiac disease; intolerance to the prescribed drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Waist circimference. Timepoint: at the start and end of the study. Method of measurement: cm.;Fasting blood sugar. Timepoint: at the start and end of the study. Method of measurement: mg/dl.;Serum triglyceride. Timepoint: at the start and end of the study. Method of measurement: mg/dl.;Blood pressure. Timepoint: at the start and end of the study. Method of measurement: milimeter of mercury.;Body mass index. Timepoint: at the start and end of the study. Method of measurement: kg/m2.	—

Measure

Time frame

Waist circimference. Timepoint: at the start and end of the study. Method of measurement: cm.;Fasting blood sugar. Timepoint: at the start and end of the study. Method of measurement: mg/dl.;Serum triglyceride. Timepoint: at the start and end of the study. Method of measurement: mg/dl.;Blood pressure. Timepoint: at the start and end of the study. Method of measurement: milimeter of mercury.;Body mass index. Timepoint: at the start and end of the study. Method of measurement: kg/m2.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Azariun

Qazvin University of Medica Sciences

dr.houshmand@yahoo.com+98 28 3335 6696

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026